FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206459817> ?p ?o ?g. }

• W3206459817 abstract "There have been many meta-analyses for statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) to evaluate clinical outcomes, but the efficacy and safety of different intensity of these three drugs on clinical outcomes was absent. PCSK9i, ezetimibe, and statins were divided into seven interventions as follows: including PCSK9i + high-intensity statins (P9i+HT), PCSK9i + moderate-intensity statins (P9i+MT), ezetimibe + high-intensity statins (Eze+HT), ezetimibe + moderate-intensity statins (Eze+MT), high-intensity statins (HT), moderate-intensity statins (MT), and low-intensity statins (LT). The risk ratios (RR) and 95% confidence intervals (CI) were calculated to evaluate the clinical outcomes in all randomized controlled trials included. In traditional meta-analysis, the more intensive treatment had a lower risk of all-cause mortality (RR 0.91, 95% CI 0.88-0.95), cardiovascular mortality (RR 0.89, 95% CI 0.86-0.92), myocardial infarction (RR 0.79, 95% CI 0.77-0.81), coronary revascularization (RR 0.80, 95% CI 0.76-0.84), and cerebrovascular events (RR 0.84, 95% CI 0.80-0.88) compared with the less intensive treatment. However, the more intensive treatment had a higher risk of new-onset diabetes (RR 1.08, 95% CI 1.04-1.12). The network meta-analysis demonstrated that P9i+HT, P9i+MT, HT, and MT were significantly associated with a risk reduction in coronary revascularization and cerebrovascular events compared with PLBO. LT could effectively reduce the risk of cardiovascular mortality (RR 0.71, 95% CI 0.54-0.92), MI (RR 0.67, 95% CI 0.54-0.82), and coronary revascularization (RR 0.77, 95% CI 0.65-0.91) compared with PLBO. P9i+HT was superior to HT in reducing the risk of MI (RR 0.78, 95% CI 0.68-0.90), coronary revascularization (RR 0.84, 95% CI 0.73-0.96), and cerebrovascular events (RR 0.78, 95% CI 0.64-0.95). However, compared with PLBO, P9i+HT, HT, and MT could increase the risk of new-onset diabetes (RR 1.23, 95% CI 1.11-1.37; RR 1.23, 95% CI 1.14-1.33; RR 1.09, 95% CI 1.02-1.15, respectively). In conclusion, PCSK9i added to background statins may be recommended as preferred lipid-lowering therapy, and did not increase the additional risk of new-onset diabetes. The safety and efficacy of ezetimibe was not superior to that of statins. LT can be recommended as the initial therapy." @default.
• W3206459817 created "2021-10-25" @default.
• W3206459817 creator A5022610350 @default.
• W3206459817 creator A5024247850 @default.
• W3206459817 creator A5033266181 @default.
• W3206459817 creator A5059065690 @default.
• W3206459817 creator A5061887142 @default.
• W3206459817 creator A5081562437 @default.
• W3206459817 date "2021-10-21" @default.
• W3206459817 modified "2023-09-27" @default.
• W3206459817 title "Efficacy and Safety of Lipid-Lowering Drugs of Different Intensity on Clinical Outcomes: A Systematic Review and Network Meta-Analysis" @default.
• W3206459817 cites W121888607 @default.
• W3206459817 cites W1500963439 @default.
• W3206459817 cites W1520609538 @default.
• W3206459817 cites W1523152575 @default.
• W3206459817 cites W1546258268 @default.
• W3206459817 cites W1816597323 @default.
• W3206459817 cites W1968240228 @default.
• W3206459817 cites W2001328643 @default.
• W3206459817 cites W2018711158 @default.
• W3206459817 cites W2031185570 @default.
• W3206459817 cites W2068520517 @default.
• W3206459817 cites W2097571126 @default.
• W3206459817 cites W2100800328 @default.
• W3206459817 cites W2106285889 @default.
• W3206459817 cites W2107295258 @default.
• W3206459817 cites W2110601215 @default.
• W3206459817 cites W2116045728 @default.
• W3206459817 cites W2118667643 @default.
• W3206459817 cites W2120289695 @default.
• W3206459817 cites W2126452437 @default.
• W3206459817 cites W2126563293 @default.
• W3206459817 cites W2126678006 @default.
• W3206459817 cites W2129750583 @default.
• W3206459817 cites W2130192610 @default.
• W3206459817 cites W2130636082 @default.
• W3206459817 cites W2131275408 @default.
• W3206459817 cites W2132064529 @default.
• W3206459817 cites W2134120087 @default.
• W3206459817 cites W2135631433 @default.
• W3206459817 cites W2137983259 @default.
• W3206459817 cites W2139168645 @default.
• W3206459817 cites W2141898196 @default.
• W3206459817 cites W2150144996 @default.
• W3206459817 cites W2155598961 @default.
• W3206459817 cites W2156098321 @default.
• W3206459817 cites W2156880046 @default.
• W3206459817 cites W2159449551 @default.
• W3206459817 cites W2162430779 @default.
• W3206459817 cites W2164976094 @default.
• W3206459817 cites W2166910397 @default.
• W3206459817 cites W2167045683 @default.
• W3206459817 cites W2313998826 @default.
• W3206459817 cites W2314193179 @default.
• W3206459817 cites W2322095705 @default.
• W3206459817 cites W2554832534 @default.
• W3206459817 cites W2568987715 @default.
• W3206459817 cites W2569797875 @default.
• W3206459817 cites W2596179513 @default.
• W3206459817 cites W2596236174 @default.
• W3206459817 cites W2606701238 @default.
• W3206459817 cites W2754562397 @default.
• W3206459817 cites W2761079932 @default.
• W3206459817 cites W2770626913 @default.
• W3206459817 cites W2789251847 @default.
• W3206459817 cites W2793867011 @default.
• W3206459817 cites W2800876320 @default.
• W3206459817 cites W2811289319 @default.
• W3206459817 cites W2899997727 @default.
• W3206459817 cites W2909436318 @default.
• W3206459817 cites W2914546434 @default.
• W3206459817 cites W2922829459 @default.
• W3206459817 cites W2940327706 @default.
• W3206459817 cites W2942412515 @default.
• W3206459817 cites W2960913366 @default.
• W3206459817 cites W2976451193 @default.
• W3206459817 cites W2991792334 @default.
• W3206459817 cites W2996190040 @default.
• W3206459817 cites W3016255169 @default.
• W3206459817 cites W3022055712 @default.
• W3206459817 cites W3028258336 @default.
• W3206459817 cites W3044040073 @default.
• W3206459817 cites W3046033709 @default.
• W3206459817 cites W3048050079 @default.
• W3206459817 cites W3049649840 @default.
• W3206459817 cites W3061843793 @default.
• W3206459817 cites W3094631662 @default.
• W3206459817 cites W3097566011 @default.
• W3206459817 cites W3099601560 @default.
• W3206459817 cites W3135240275 @default.
• W3206459817 cites W3139070968 @default.
• W3206459817 cites W3155678673 @default.
• W3206459817 cites W3176049367 @default.
• W3206459817 cites W3183857127 @default.
• W3206459817 cites W3195809642 @default.
• W3206459817 cites W3196062050 @default.
• W3206459817 cites W38523360 @default.
• W3206459817 cites W4238580056 @default.
• W3206459817 cites W4244516790 @default.
• W3206459817 cites W424467158 @default.

• next